|
Isotechnika Announces That Lux Biosciences’ Phase 3 Uveitis Study Did Not …
Equities.com “Our emphasis on nephrology remains intact and we continue to have full confidence in the potential of voclosporin to address significant unmet medical needs like kidney transplant rejection and lupus nephritis.” About Isotechnika Pharma Inc … |
|
Isotechnika Announces That Lux Biosciences’ Phase 3 Uveitis Study Did Not …
Stockhouse “Our emphasis on nephrology remains intact and we continue to have full confidence in the potential of voclosporin to address significant unmet medical needs like kidney transplant rejection and lupus nephritis.” About Isotechnika Pharma Inc … |
|
Isotechnika Announces That Lux Biosciences’ Phase 3 Uveitis Study Did Not …
GlobeNewswire (press release) “Our emphasis on nephrology remains intact and we continue to have full confidence in the potential of voclosporin to address significant unmet medical needs like kidney transplant rejection and lupus nephritis.” About Isotechnika Pharma Inc … |
|
Biomarkers could give early warning of late heart transplant rejection
MarketWatch (press release) “All transplant patients eventually progress to chronic rejection,” according to Briscoe, director of the TRP and a nephrologist with a long-standing interest in molecular monitoring for transplant rejection. “It’s a slow process that evolves over … |
Diabetics tied up as Medicare contractors split on kidney treatmentMilwaukee Journal SentinelThe treatment has a higher rate of side effects, including acute rejection. The side effects can be treated but have their own complications. The treatment als…
From cakes to tech, bold startups defy Portugal crisisGibraltar ChronicleCell2B is preparing for clinical trials of promising cell therapies aimed at eliminating transplant rejection in humans, after which the founders do not rule out a share offering….
From cakes to tech, bold startups defy Portugal crisisGMA NewsCell2B is preparing for clinical trials of promising cell therapies aimed at eliminating transplant rejection in humans, after which the founders do not rule out a share offering. Nuno Carva…
|
Korea Advances Organ Transplants with Stem Cell Therapy
Arirang News In previous surgeries, the use of immuno-suppressants was necessary to prevent an acute rejection by the body.” The cutting-edge medical operation is a first for Korea and also another step towards a drug-free, universal organ transplant system. Paul … |
Laboratory instruments are seen at the Cell2B biomedical company near LisbonReuters AlertNetLaboratory instruments are seen at the Cell2B biomedical company near Lisbon December 18, 2012. Cell2B is preparing for clinical trials of promising cell therap…
San Francisco ChronicleInsight: From cakes to tech, bold startups defy Portugal crisisYahoo!7 NewsCell2B is preparing for clinical trials of promising cell therapies aimed at eliminating transplant rejection in humans, after which the founders do not r…